Alpine Fox Capital LLC Acquires Shares of 1,000 Regeneron Pharmaceuticals, Inc. $REGN

Alpine Fox Capital LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, Holdings Channel.com reports. The firm acquired 1,000 shares of the biopharmaceutical company’s stock, valued at approximately $562,000. Regeneron Pharmaceuticals accounts for approximately 0.2% of Alpine Fox Capital LLC’s portfolio, making the stock its 11th largest holding.

Several other institutional investors have also modified their holdings of the company. Osaic Holdings Inc. lifted its holdings in Regeneron Pharmaceuticals by 55.2% during the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock worth $9,607,000 after buying an additional 6,073 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its position in shares of Regeneron Pharmaceuticals by 153.4% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after acquiring an additional 73,176 shares in the last quarter. PGGM Investments increased its holdings in shares of Regeneron Pharmaceuticals by 9.7% in the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock valued at $52,057,000 after acquiring an additional 8,187 shares during the last quarter. Sound Shore Management Inc CT purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $64,677,000. Finally, Rakuten Investment Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $33,121,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 0.1%

REGN opened at $745.77 on Friday. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The business’s 50 day moving average is $769.73 and its two-hundred day moving average is $694.92. The firm has a market cap of $78.84 billion, a price-to-earnings ratio of 17.94, a price-to-earnings-growth ratio of 2.00 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the company earned $12.07 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were paid a dividend of $0.94 per share. The ex-dividend date was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on REGN shares. Barclays assumed coverage on Regeneron Pharmaceuticals in a research note on Friday, March 6th. They set an “overweight” rating and a $923.00 target price for the company. HSBC upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the stock from $627.00 to $860.00 in a research report on Wednesday, January 7th. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Finally, JPMorgan Chase & Co. increased their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $802.27.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,274 shares of company stock worth $4,142,738 in the last quarter. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.